Cabaletta Bio Inc’s recent filing unveils that its Chief Medical Officer Chang David J. acquired Company’s shares for reported $19888.0 on Jan 21 ’26. In the deal valued at $2.26 per share,8,800 shares were bought. As a result of this transaction, Chang David J. now holds 8,800 shares worth roughly $27984.0.
Then, Binder Gwendolyn bought 11,312 shares, generating $24,763 in total proceeds. Upon buying the shares at $2.19, the President, Science & Tech. now owns 31,312 shares.
Before that, Tomasello Shawn bought 22,725 shares. Cabaletta Bio Inc shares valued at $50,322 were divested by the Director at a price of $2.21 per share. As a result of the transaction, Tomasello Shawn now holds 22,725 shares, worth roughly $72265.5.
A number of analysts have revised their coverage, including Evercore ISI’s analysts, who decreased its forecast for the stock in mid December from “an Outperform” to “an In-line”. Wells Fargo also remained covering CABA and has decreased its forecast on December 19, 2024 with a “an Equal weight” recommendation from previously “an Overweight” rating. UBS started covering the stock on October 10, 2024. It rated CABA as “a Buy”.
Price Performance Review of CABA
On Friday, Cabaletta Bio Inc [NASDAQ:CABA] saw its stock jump 8.16% to $3.18. Over the last five days, the stock has gained 52.88%. Cabaletta Bio Inc shares have risen nearly 25.20% since the year began. Nevertheless, the stocks have risen 45.21% over the past one year.
How much short interest is there in Cabaletta Bio Inc?
A steep rise in short interest was recorded in Cabaletta Bio Inc stocks on 2025-12-31, growing by 0.68 million shares to a total of 18.8 million shares. Yahoo Finance data shows the prior-month short interest on 2025-11-28 was 18.11 million shares. There was a rise of 3.63%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on February 05, 2024 when Jefferies began covering the stock and recommended ‘”a Buy”‘ rating along with a $36 price target.
